- Jan 2015: Intercept Pharma Inc. (ICPT) received Breakthrough Therapy Designation from the FDA for Obeticholic Acid (OCA) for nonalcoholic steatohepatitis (NASH) with liver fibrosis.
heikin daily 8/15
weekly 8/15
Jan 2015
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver diseases utilizing its proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trial to treat portal hypertension; in Phase IIb clinical trial for the treatment of nonalcoholic steatohepatitis; and in Phase IIa clinical trial to treat bile acid diarrhea. The company was founded in 2002 and is headquartered in New York, New York.
Address
18 Desbrosses Street
NEW YORK, NY 10013
United States
NEW YORK, NY 10013
United States
Website
www.interceptpharma.comKey stats and ratios
| Q3 (Sep '13) | 2012 | |
| Net profit margin | -7828.39% | -1784.18% |
| Operating margin | -2738.54% | -773.21% |
| EBITD margin | - | -764.99% |
| Return on average assets | -78.88% | -66.30% |
| Return on average equity | -122.85% | -146.15% |
| Employees | 25 |
No comments:
Post a Comment